Table 2 Clinicopathological characteristics of patients and their correlation with ErbB1/3 protein expression
From: ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer
| Â | Total | ErbB1 | p | ErbB3 | p | ErbB1 and ErbB3 | p | |||
|---|---|---|---|---|---|---|---|---|---|---|
Over expression | Normal | Over expression | Normal | Over expression | Normal | |||||
Age | 96 (40–80) |  |  |  |  |  |  |  |  |  |
Sex | Â | Â | Â | 0.313 | Â | Â | 0.485 | Â | Â | 0.791 |
 Male | 38 (76%) | 19 (50%) | 19 (50%) |  | 16 (42.1%) | 22 (57.9%) |  | 11 (28.9%) | 27 (71.1%) |  |
 Female | 12 (24%) | 4 (33.3%) | 8 (66.7%) |  | 4 (33.3%) | 8 (66.7%) |  | 3 (25%) | 9 (75%) |  |
Size | 82 (30–100) |  |  |  |  |  |  |  |  |  |
Location | Â | Â | Â | 0.730 | Â | Â | 0.485 | Â | Â | 0.797 |
 Cardia | 12 (24%) | 5 (41.7%) | 7 (58.3%) |  | 4 (33.3%) | 8 (66.7%) |  | 3 (25%) | 9 (75%) |  |
 Non-cardia | 38 (76%) | 18 (47.4%) | 20 (52.6%) |  | 16 (42.1%) | 22 (57.9%) |  | 11 (28.9%) | 27 (71.1%) |  |
Lauren classification | Â | Â | Â | 0.999 | Â | Â | 0.999 | Â | Â | 0.550 |
 Intestinal | 47 (94%) | 22 (46.8%) | 25 (53.2%) |  | 19 (40.4%) | 28 (59.6%) |  | 14 (29.8%) | 33 (70.2%) |  |
 Diffuse | 3 (6%) | 1 (33.3%) | 2 (66.7%) |  | 1 (33.3%) | 2 (66.7%) |  | – | 3 (100%) |  |
Macroscopy |  |  |  | 0.028 |  |  | < 0.05 |  |  | < 0.05 |
 Infiltrative | 18 (36%) | 12 (66.7%) | 6 (33.3%) |  | 17 (94.4%) | 1 (5.6%) |  | 12 (66.7%) | 6 (33.3%) |  |
 Ulceroinfiltrative | 32 (64%) | 11 (34.4%) | 21 (65.6%) |  | 3 (9.4%) | 29 (90.6%) |  | 2 (6.2%) | 30 (93.8%) |  |
Differentiation |  |  |  | 0.028 |  |  | < 0.05 |  |  | < 0.05 |
 Poorly | 20 (40%) | 13 (65%) | 7 (35%) |  | 19 (95%) | 1 (5%) |  | 13 (65%) | 7 (35%) |  |
 Not-poorly | 30 (60%) | 10 (33.3%) | 20 (66.7%) |  | 1 (3.3%) | 29 (96.7%) |  | 1 (3.3%) | 29 (96.7%) |  |
Stage (TNM) |  |  |  | 0.027 |  |  | < 0.05 |  |  | < 0.05 |
 I–II | 28 (56%) | 9 (32.1%) | 19 (67.9%) |  | – | 28 (100%) |  | – | 28 (100%) |  |
 III–IV | 22 (46%) | 14 (63.6%) | 8 (36.4%) |  | 20 (90.9%) | 2 (9.1%) |  | 14 (63.8%) | 8 (36.2%) |  |
Tumor depth of invasion | Â | Â | Â | 0.999 | Â | Â | 0.254 | Â | Â | 0.550 |
 T1–T2 | 3 (6%) | 1 (33.3%) | 2 (66.7%) |  | – | 3 (100%) |  | – | 3 (100%) |  |
 T3–T4 | 47 (94%) | 22 (46.8%) | 25 (53.2%) |  | 20 (42.6%) | 27 (57.4%) |  | 14 (29.8%) | 33 (70.2%) |  |
Lymph node metastasis | Â | Â | Â | 0.493 | Â | Â | 0.503 | Â | Â | 0.999 |
 Positive | 48 (98%) | 23 (47.9%) | 25 (52.1%) |  | 20 (41.7%) | 28 (58.3%) |  | 14 (29.2%) | 34 (70.8%) |  |
 Negative | 2 (2%) | – | 2 (100%) |  | – | 2 (100%) |  | – | 2 (100%) |  |
Recurrence |  |  |  | 0.013 |  |  | < 0.05 |  |  | < 0.05 |
 Positive | 21 (42%) | 14 (66.7%) | 7 (33.3%) |  | 20 (95.2%) | 1 (4.8%) |  | 14 (66.7%) | 7 (33.3%) |  |
 Negative | 29 (58%) | 9 (31%) | 20 (69%) |  | – | 29 (100%) |  | – | 29 (100%) |  |